modelCetirizine

Diagram of Cetirizine

Extends from Pharmacolibrary.Drugs.ATC.S.S01GX12.

Information

name:Cetirizine
ATC code:S01GX12
route:oral
compartments:1
dosage:10mg
volume of distribution:0.54L
clearance:0.42L/h/kg
other parameters in model implementation

Cetirizine is a second-generation antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching. It is commonly used for the treatment of allergic rhinitis and chronic urticaria. Cetirizine is approved and widely used today.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose.

References

  1. Paine, SW, et al., & Hincks, PR (2022). Plasma and urine pharmacokinetics of hydroxyzine and cetirizine following repeated oral administrations to exercised horses. Journal of veterinary pharmacology and therapeutics 45(1) 46–53. DOI:10.1111/jvp.13010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34469007

  2. Knych, HK, et al., & McKemie, DS (2019). Pharmacokinetics of hydroxyzine and cetirizine following oral administration of hydroxyzine to exercised Thoroughbred horses. Journal of veterinary pharmacology and therapeutics 42(6) 617–623. DOI:10.1111/jvp.12808 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31490561

  3. Hussein, Z, et al., & Stockis, A (2005). Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. British journal of clinical pharmacology 59(1) 28–37. DOI:10.1111/j.1365-2125.2005.02242.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15606437

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)